Gritstone inks up to $433M contract with BARDA for 10,000-person Covid-19 vaccine trial

Grit­stone bio will get up to $433 mil­lion from the US gov­ern­ment to run a Phase IIb tri­al ear­ly next year test­ing its self-am­pli­fy­ing mR­NA vac­cine can­di­date with an ap­proved Covid-19 jab, the biotech said af­ter the mar­kets closed Wednes­day.

The Emeryville, CA, and Boston biotech nabbed the con­tract as part of the fed­er­al gov­ern­ment’s $5 bil­lion Project NextGen, a fol­low-up to Op­er­a­tion Warp Speed to cre­ate new vac­cines and drugs for the coro­n­avirus pan­dem­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.